DiagnosTear

Company Overview

Snapshot

Founded in September 2013 by Eran Eilat, DiagnosTear operates with 1–10 employees. The company has raised $4.58M across five funding rounds from two investors. In December 2024, DiagnosTear became publicly listed on the CSE.

Business overview

DiagnosTear specializes in developing technology for the diagnosis and treatment of dry eye syndrome. The company's core product, the TeaRx assay, facilitates the diagnosis, treatment, and monitoring of dry eye syndrome by analyzing tear fluid parameters. This assay utilizes reagents that create color reactions for semi-quantitative assessment, aiding in treatment selection and monitoring. TeaRx enables screening and monitoring by examining up to five varieties of tear fluid through a simple device placed under the lower eyelid. DiagnosTear operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices, serving healthcare providers globally.

Strategic signal

In May 2026, DiagnosTear secured exclusive global rights to the CLARIFY Eye Imaging Platform for needle-free blood diagnostics. This strategic move expands the company's diagnostic capabilities beyond dry eye syndrome and positions it to enter the broader blood diagnostics market, signaling a significant diversification and growth opportunity for investors.

Company Intelligence Q&A

What is DiagnosTear's primary focus?

DiagnosTear specializes in technology for the diagnosis and treatment of dry eye syndrome, developing an assay designed to facilitate diagnosis, treatment, and monitoring by examining parameters in tear fluid.

When did DiagnosTear go public?

DiagnosTear became publicly listed on the Canadian Securities Exchange (CSE) in December 2024.

What is the TeaRx assay?

The TeaRx assay is DiagnosTear's core product, based on reagents that create color reactions with tear film for semi-quantitative assessment of dry eye syndrome parameters, aiding in diagnosis and treatment selection.

What was a recent significant strategic development for DiagnosTear?

In May 2026, DiagnosTear secured exclusive global rights to the CLARIFY Eye Imaging Platform, enabling needle-free blood diagnostics.

Has DiagnosTear initiated any collaborations for its TeaRx product?

In November 2025, DiagnosTear Technologies announced the initiation of a collaboration with LV Prasad Eye Institute for advancing the clinical validation of its TeaRx Red Eye Diagnostic Test.